NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Viatris Inc. (VTRS) Stock Analysis

Viatris Inc. (VTRS) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

VTRS

$16.88

−$0.06 (−0.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VTRS with… →

VTRS Key Statistics

As of Sep 4, 2026
Trading
Open
$16.81
Previous Close
$16.94
Day's Range
16.67–17.02
52-Week Range
9.43–18.39
Volume
5.73M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$19.39B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
6.33
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.05
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.37
Financials (FY)
Revenue (FY)
$14.30B−2.98%
Net Income (FY)
−$3.51B
Profit marginThe share of revenue left as profit after all costs and taxes.
−2.79%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.15B
1-Year Return
+69.20%
Dividend and dates
Dividend
$0.48+2.84%
Ex-Dividend Date
August 21, 2026
Earnings Date
November 5, 2026
Avg Volume
9.72M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VTRS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+38.78%
2025+5.08%
2024+19.68%
2023+2.06%
2022−14.29%
2021−26.12%
2020−6.77%
2019−26.64%
2018−35.24%
2017+10.90%
2016 (partial year)−21.97%

As of September 4, 2026.

VTRS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.30B−$3.51B−24.6%
2024$14.74B−$634.20M−4.3%
2023$15.43B$54.70M0.4%
2022$16.26B$2.08B12.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.30B$5.01B$253.50M−$3.51B−24.6%
2024$14.74B$5.62B$710.30M−$634.20M−4.3%
2023$15.43B$6.44B$1.56B$54.70M0.4%
2022$16.26B$6.50B$1.66B$2.08B12.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VTRS Dividend History

$0.48+0.0% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.363—
2025$0.484+0.0%
2024$0.484+0.0%
2023$0.484+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.363—
2025$0.484+0.0%
2024$0.484+0.0%
2023$0.484+0.0%
2022$0.484+45.5%
2021$0.333—

Most recent payment: $0.12 per share, ex-dividend August 21, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

VTRS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricVTRSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.322.3043% below
Profit margin−2.79%−3.14%0.3 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Viatris Inc. (VTRS) is capitalised at $19.39B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 30,000.

VTRS last closed at $16.88 on September 4, 2026. That is −$0.06 (−0.35%) against the previous close. The 52-week range on file runs from $9.43 to $18.39. The latest close sits 79% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $14.30B. That is −2.98% against the prior fiscal year, when revenue was $14.74B. The same year closed with a net loss of $3.51B. Profit margin runs at −2.79%. That is 0.3 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.37.

Across the 4 fiscal years on file, revenue moves from $16.26B in 2022 to $14.30B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 6.33. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.05. Measured against sales, the shares trade at 1.32 times revenue. On price-to-sales that is 42.71% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned +69.20%. Across 10 years the annualized return works out at −6.17%. Beta against the wider market is reported at 0.88. Annualized volatility over the trailing 10 years is 36.62%.

Growth & Income

The trailing dividend yield is 2.84%. That is 0.8 percentage points above the Drug Manufacturers - Specialty & Generic median yield of 2.06%. The indicated annual rate is $0.48 a share. The ex-dividend date on file is August 21, 2026. Dividends are recorded for 6 calendar years; 2026 shows 3 payments totalling $0.36 a share. The year before, 2025, totalled $0.48 a share.

So far in 2026 the price is +38.78%. Across the complete calendar years on file, 2024 returned +19.68% and 2018 returned −35.24%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Viatris Inc. (VTRS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Viatris Inc. VTRS $19.39B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Viatris Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 NBIX

Neurocrine Biosciences, Inc.

$15.82B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Viatris Inc.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Visit website →